
Labs in Court: Two EKRA-Related Cases and Some Usual Suspects
Recent enforcement actions involved usual targets such as COVID-19, genetic, and urine drug testing, but EKRA also made an appearance

Recent enforcement actions involved usual targets such as COVID-19, genetic, and urine drug testing, but EKRA also made an appearance

Recent DOJ settlements continue to focus on issues involving medical necessity and marketer compensation

COVID-19-related schemes dominated recent enforcement efforts, which include a national healthcare fraud enforcement action

Genetic testing related fraud was a theme in recent enforcement actions involving medical laboratories and lab testing

Examining DOJ and OIG investigations of labs and their owners: Recent cases show continued focus on the usual enforcement targets.